Skip to main content
رجوع
Watch Compare

Bone Biologics Corp

جودة البيانات: 83%
مُدرج أيضًا باسم BBLGW Nasdaq
BBLG
Nasdaq Manufacturing Measuring & Analyzing Instruments
KWD 1.26
▼ KWD 0.02 (-1.56%)
القيمة السوقية: 2.26 M
السعر
KWD 1.26
القيمة السوقية
2.26 M
نطاق اليوم
KWD 1.24 — KWD 1.29
نطاق 52 أسبوعًا
KWD 1.05 — KWD 6.75
حجم التداول
7,293
فتح KWD 1.29
متوسط 50 يوم / 200 يوم
KWD 1.29
2.40% below
متوسط 50 يوم / 200 يوم
KWD 2.09
39.61% below

Quick Summary

النقاط الرئيسية

Negative free cash flow of -2.69 M

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-49.30%
أعلى من متوسط القطاع (-51.02%)
ROIC-40.52%
Net MarginN/A
Op. MarginN/A

الأمان

Debt / Equity
N/A
Current Ratio19.00
Interest CoverageN/A

التقييم

PE (TTM)
-0.73
أعلى من متوسط القطاع (-1.98)
P/B Ratio0.38
EV/EBITDAN/A
Dividend YieldN/A

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (44 نظير)
المقياس السهم وسيط القطاع
P/E -0.7 -2.0
P/B 0.4 5.1
ROE % -49.3 -51.0
Net Margin % — -150.2
Rev Growth 5Y % — 9.3
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -3.11 M
ROE -49.30% ROA -46.57%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -2.69 M
ROIC -40.52% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 19.00
Interest Coverage N/A Asset Turnover N/A
Working Capital 6.02 M Tangible Book Value 6.02 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.73 Forward P/E N/A
P/B Ratio 0.38 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -118.97%
Market Cap 2.26 M Enterprise Value 2.26 M
Per Share
EPS (Diluted TTM) -2.65 Revenue / Share N/A
FCF / Share -1.50 OCF / Share -1.50
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 86.56%
SBC-Adj. FCF -2.92 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -3.11 M -4.11 M -8.95 M -1.48 M -1.61 M
EPS (Diluted) -2.65 -4.83 -34.01 — —
Gross Profit — — — — —
Operating Income -3.23 M -4.22 M -9.43 M -3.67 M -1.10 M
EBITDA — — — — —
R&D Expenses 1.06 M 2.13 M 6.91 M 1.58 M 82,044.0
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — — 1,868.0 — —
Income Tax — — — — 1,600.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 5.80 M 3.86 M 3.74 M 8.50 M 6.68 M
Total Liabilities 418,587.0 377,712.0 831,402.0 2.55 M 99,909.0
Shareholders' Equity 5.38 M 3.48 M 2.91 M 5.95 M 6.58 M
Total Debt — — — — —
Cash & Equivalents — — — — 6.68 M
Current Assets 5.80 M 3.86 M 3.74 M — —
Current Liabilities 418,587.0 377,712.0 831,402.0 2.55 M —